(RAY-dee-um … dy-KLOR-ide)
This page contains brief information about radium 223 dichloride (Xofigo) and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Radium 223 dichloride is approved to treat:
- Prostate cancer that is castrate resistant (has not responded to treatments that lower testosterone levels). It is used in patients whose cancer has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs.
Radium 223 dichloride is also being studied in the treatment of other types of cancer.
More About Radium 223 Dichloride
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Hormone Therapy for Prostate Cancer
Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age
Clinical Trials Accepting Patients
Find Clinical Trials for Radium Ra 223 Dichloride – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
